
M&A, IPOs Snarled By Policy Reality in Q1 as Pharmas Opt for Licensing Deals
M&A value in biopharma climbed 101% in the first quarter of the year as compared to the last three months of 2024, setting off a wave of optimism and excitement. But that cheer was quickly met with reality and drugmakers are now back to being cautious, …